UPDATED: Nestlé is betting $525M on a bid to pioneer world's first microbiome drug
After fighting a years-long uphill battle with its oral microbiome candidate SER-109, Seres Therapeutics finally got the Phase III results it was looking for last August. And on Thursday, the company inked a $525 million deal with Nestlé Health Science to commercialize the drug — that is, if it can win over the FDA.
SER-109 is an oral, live microbiome therapy being developed for patients with recurrent C. difficile infection, a leading cause of hospital-acquired infections in the US. The candidate is made up of purified Firmicutes spores (a type of bacteria) manufactured from the stool of healthy donors, and is designed to rapidly repopulate the microbiome in the gut.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.